Novocure fails PhIII in platinum-resistant ovarian cancer

Novo­cure’s ovar­i­an can­cer treat­ment failed to meet the pri­ma­ry end­point of over­all sur­vival in a Phase III tri­al, send­ing the New Jer­sey biotech’s stock price down 32% on Mon­day morn­ing.

Novo­cure said Mon­day that a com­bi­na­tion of its tu­mor treat­ing field ther­a­py, called TTFields, and the chemother­a­py pa­cli­tax­el did not meet the pri­ma­ry end­point of over­all sur­vival in pa­tients who have un­der­gone mul­ti­ple lines of treat­ment in ovar­i­an can­cer and are re­sis­tant to plat­inum-based treat­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.